Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... , ... Sleepless nights will become obsolete as Luzi , a sophisticated ... on June 23. Sound sleepers and the sleep deprived both will love Luzi for ... the integration of the Bluetooth speaker, alarm clock and ability to charge various devices, ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:6/30/2015)... Japan , July 1, 2015 R-Japan Co.,Ltd. ... on the Safety of Regenerative Medicine from the Ministry of ... on June 29, 2015. The fact that ... processing facility through the auditing from Pharmaceuticals and Medical Devices ... the application, allows it to provide stem cell manufacturing service ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... one of the world,s leading research and advisory firms for ... marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive ... 2008 to $5.2 billion in 2018 in the United States, ... , The new Pharmacor report entitled Psoriasis ...
... ... dye test alternative using innovative laser technology has been installed at the ... Bayer China has acquired Sepha ’s ‘BlisterScan’ machines for non-destructive leak testing on ... ...
... ... Wide range of new peptide synthesis reagents and catalogue peptides. New pricing positions Mimotopes ... ... -- Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc. (NASDAQ Capital Market: CBTE), ...
Cached Biology Technology:Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 3Mimotopes Launches Online Peptide Superstore 2Mimotopes Launches Online Peptide Superstore 3
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
(Date:6/17/2015)... Calif. , June 17, 2015  Synaptics ... human interface solutions, today announced that Xiaomi, one ... the Synaptics ® ClearPad ® family ... display driver integrated circuits (DDICs) for its latest ... By leveraging ClearPad for full in-cell display solutions ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... honeybee hives arrests the growth of prostate cancer cells and ... at the University of Chicago Medicine. Caffeic acid phenethyl ... propolis, the resin used by bees to patch up holes ... natural remedy for conditions ranging from sore throats and allergies ...
... Biology Reports published today argues that recent advances ... of the global demand for liquid transportation fuels, drastically reducing ... burning fossil fuels, without having an impact on food production. ... of detrimental climate change is the emission of greenhouse gasses ...
... brain activity in the rat brain that play a ... decision-making. The discovery, which builds on the team,s previous ... post-traumatic stress syndrome. The researchers previously identified patterns ... region critical for memory storage. The patterns sometimes represented ...
Cached Biology News:Beehive extract shows potential as prostate cancer treatment 2Beehive extract shows potential as prostate cancer treatment 3Better plants for biofuels 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3
... Synthetic peptide derived from the C-terminal region ... kinase C zeta isoform (PKCzeta). Specificity: ... protein. Recognizes PKCzeta and PKMzeta (PKCzeta ... Reactivity: Mouse Rat (positive controls: mouse ...
...
Request Info...
Request Info...
Biology Products: